News
The trial evaluates R3 Vascular's next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more than 200 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback